Opinion|Videos|July 2, 2024
Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
Advertisement
Episodes in this series
- Based on your experience, how have topical treatments evolved beyond the use of topical steroids and topical calcineurin inhibitors?
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Judge Denies Preliminary Injunction in Medicaid Work Requirements Case
2
FDA Panel Backs 6 Peptides for Compounding
3
AHRQ Grant Freeze Halts Patient Safety Research Nationwide
4
FDA Advisory Panel Votes Against Approval of Deramiocel for DMD
5